Tonix Pharmaceuticals
TNXP
18 hedge funds and large institutions have $4.51M invested in Tonix Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
24% more capital invested
Capital invested by funds: $3.63M → $4.51M (+$879K)
0% less ownership
Funds ownership: 0% → 0% (-0%)
18% less funds holding
Funds holding: 22 → 18 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.24M |
| 2 |
Morgan Stanley
New York
|
+$429K |
| 3 |
JP Morgan Chase
New York
|
+$223K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$137K |
| 5 |
State Street
Boston,
Massachusetts
|
+$137K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.92M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$635K |
| 3 |
VF
Virtu Financial
New York
|
-$103K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$34.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$34.3K |
TNXP Hedge Fund Activity: Q1 2023 in Review
18 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q1 2023, worth a combined $4.51M — up 24% from $3.63M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TNXP and 1 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 10 added.
The largest buyer was Vanguard Group, adding an estimated $1.24M. The largest seller was Tang Capital Management, cutting an estimated $2.92M.
- 18 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q1 2023, down from 22 in Q4 2022.
- Funds reported $4.51M of Tonix Pharmaceuticals stock for Q1 2023, up 24% quarter-over-quarter.
- 1 fund opened new Tonix Pharmaceuticals positions in Q1 2023 and 5 closed out, a net change of -4 holders.
- The largest Tonix Pharmaceuticals buyer in Q1 2023 was Vanguard Group, an estimated $1.24M added.
- The largest Tonix Pharmaceuticals seller in Q1 2023 was Tang Capital Management, an estimated $2.92M sold.
Based on aggregated 13F filings for Q1 2023.